A Clinical Trial for Chronic Lymphocytic Leukemia

Chronic Lymphocytic Leukemia is the most common kind of leukemia in adults. Current therapy is extremely unpleasant and often (usually) fails. There is a very large number of clinical trials of new therapies mostly immunotherapies. They are based on the fact that CLL cells are B-cells which express CD20.

One such trial is NCT03759184 Human IL-15 (rhIL-15) and Obinutuzumab for Relapsed and Refractory Chronic Lymphocyte Leukemia

This is a therapy which isn’t too horrible. The doctors are having some trouble recruiting patients (as noted above there are many trials attempting to treat people with relapsed and refractory CLL).

Complete disclosure: one of those doctors is my dad.

People with relapsed and refractory CLL who are interested in considering whether to enrol in the trial can

Contact: NCI Medical Oncology Referral Office (240) 760-6050 ncimo_referrals@mail.nih.gov